3p’s Aseptic Fill2weighttm Powder Dispenser: an Enabling Technology for Parenteral Reconstitution Devices

Traditional small-molecule pharmaceutical blockbusters are increasingly subject to generic price competition as they drop off the “patent cliff”. Large pharmaceutical companies are banking on replacing their lost revenue streams with large-molecule biological blockbusters. These are developed through biological processes using living cells and organisms. The birth of the biologicals industry can be charted back to 1976 when biochemistry professor, Robert Swanson, met with venture capitalist, Herbert Boyer, in California to rough-out a business plan for what became The trend within the pharmaceutical industry towards large-molecule biologic drug substances is well documented. Due to the fragile nature of these compounds, they often need either coldchain logistics or reconstitution prior to administration. Innovation in reconstitution devices and in formulations has been stifled by the inability of conventional powder handling systems to dispense small and precise amounts of reconstitution powders aseptically. This paper, from Tom Bailey, Managing Director, and Dave Seaward, Projects Director, both of 3P Innovation, describes how the company’s innovative gravimetric Fill2WeightTM system overcomes these technical challenges to enable advances in both formulations and parenteral device design. 3P’S ASEPTIC FILL2WEIGHTTM POWDER DISPENSER: AN ENABLING TECHNOLOGY FOR PARENTERAL RECONSTITUTION DEVICES